Aim: To evaluate the efficacy of a long-term course of lamivudine monotherapy in patients with anti-HBe-positive chronic hepatitis B who relapsed after the first course of either lamivudine/interferon (n = 16; Group 1) or lamivudine (n = 20; Group 2).
Methods: Biochemical and virological tests were performed every 3 months. At baseline and breakthrough, the region coding for the YMDD amino acid motif was sequenced.
Results: The length of re-treatment averaged 24 months. The virological response peaked at 6 months (94.4%), and declined to 66.7% and 50% at 12 and 24 months, respectively. The rates of breakthrough were 2.9%, 31.4% and 48.6% at 6, 12 and 24 months, respectively. By the second year, responders amounted to 62.5% and 40% in Groups 1 and 2, respectively (P = 0.10). The 18 responders at month 24 are still on therapy after 25-51 months of treatment: 14 still maintain a response, nine from Group 1 and five from Group 2.
Conclusions: Re-treatment with lamivudine can control viral replication. This effect is maintained for the initial 12 months in two-thirds of patients, but afterwards the duration of response lessens due to the development of viral resistance.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1365-2036.2003.01787.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Misuse of the Lower Limit of Detection in HBV DNA Testing and Anti-HBe Positive Status Will Significantly Impact the Diagnosis of Occult HBV Infection.
J Viral Hepat
January 2025
Department of Hepatology, Nanjing Medical University Affiliated Taizhou People's Hospital (Jiangsu Taizhou People's Hospital), Taizhou, Jiangsu, China.
The diagnosis of occult hepatitis B virus (HBV) infection (OBI) is influenced by factors such as the lower limit of detection (LOD) of the HBV DNA test. However, in clinical practice and scientific research, the lower limit of quantification (LOQ) is often misused as the LOD. This study aims to investigate the impact of misuse of the LOD of the HBV DNA test on the detection rate of OBI, as well as the risk factors for OBI.
View Article and Find Full Text PDFSeroepidemiology of hepatitis B virus (HBV) and relationship to serum transaminase levels in Indian population.
J Family Med Prim Care
June 2024
Department of Microbiology, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India.
Background: Hepatitis B virus (HBV) infection is a serious public health issue that must be addressed.
Aim: The goal of this study was to investigate the correlation between serological status for hepatitis Be antigen (HBeAg)/anti-HBe, serum transaminase levels, and serum HBV-DNA in patients with chronic HBV infection.
Methods: A retrospective observational study with 620 patients with persistent HBV infection (mean age, 36.
Evolutional transition of HBV genome during the persistent infection determined by single-molecule real-time sequencing.
Hepatol Commun
March 2023
Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Background: Although HBV infection is a serious health issue worldwide, the landscape of HBV genome dynamics in the host has not yet been clarified. This study aimed to determine the continuous genome sequence of each HBV clone using a single-molecule real-time sequencing platform, and clarify the dynamics of structural abnormalities during persistent HBV infection without antiviral therapy.
Patients And Methods: Twenty-five serum specimens were collected from 10 untreated HBV-infected patients.
Atypical serologic profiles of hepatitis B virus infection across clinical cohorts of patients in Southwestern Nigeria.
J Immunoassay Immunochem
March 2023
Department of Biological Sciences, Redeemer's University, Ede, Nigeria.
Hepatitis B virus (HBV) infection follows a natural course of events predicted by a dynamic interaction between viral antigen and the host immune system, which forms the basis for HBV serological diagnosis. These interactions may deviate from the typical serologic patterns. This study investigates the types of atypical HBV serologic profiles (AHBSP) across clinical cohorts of patients with HBV infection in southwestern Nigeria.
View Article and Find Full Text PDFPrognostic value of serological markers of hepatitis B virus infection in squamous cell cervical cancer.
J Cancer
September 2021
Department of Radiation Oncology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Center, No. 519, Kunzhou Road, Kunming 650118, People's Republic of China.
The current study aimed to investigate the prognostic value of serological markers of hepatitis B virus (HBV) infection in squamous cell cervical cancer. Squamous cell cervical cancer patients treated by concurrent chemoradiotherapy from January 2013 to December 2015 at Yunnan Cancer Hospital were retrospectively reviewed. Of a total of 277 patients, 12 (4.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!